Osiris Therapeutics, Inc. and JCR Pharmaceuticals Co., Ltd. entered into a License Agreement whereby Osiris has granted to JCR an exclusive right in Japan to its universal, adult mesenchymal stem cell (MSC) technology for use in conjunction with the treatment for hematologic malignancies using hematopoietic stem cell transplants (peripheral...
Boston Scientific Corporation (NYSE: BSX) and Osiris Therapeutics, Inc., a privately held company located in Baltimore, today announced a strategic alliance to develop and commercialize a new therapy to treat cardiovascular disease. The alliance -- which includes an equity investment by Boston Scientific -- will initially focus on applying ...
= Add to Briefcase
